Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

The G-BA Innovation Committee recommends transfer to standard care for another project in Germany

On October 17, 2022, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision, recommending the transfer to standard care for another completed project. The project relates to the improvement of the management of cancer patients.

“WiZen: Effectiveness of care in oncology centers” compared the data on the diagnostics and treatment of cancer patients in certified oncological treatment centers or non-certified healthcare facilities. Accounting data from the Scientific Institute of the AOK and data from four clinical cancer registries were used for this purpose. Information on breast cancer, lung cancer, prostate cancer, pancreatic cancer, colon cancer, tumors of the central nervous system, the head and neck area, and gynecological tumors was included in the analysis. Based on the project results, it was concluded that treatment at certified oncology centers could significantly increase the patient's chances of survival.

Innovation Fund is a vital instrument to propose and test a novel model of care (including the ones in the form of selective contracts). If the model proves valuable, it can be a subject for further dissemination in the country.

The detailed results of the projects are now being forwarded to the relevant organizations and institutions in the healthcare sector. In this regard, the respective stakeholders are requested to review the results and to consider them within their area of responsibility as far as possible.

The full details in German can be found here and here (decision for WiZen project).

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.